StockData

Tango Therapeutics vs Xilio Therapeutics

TNGX and XLO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How TNGX and XLO compare

Tango Therapeutics is the larger company, worth 86 times as much as Xilio Therapeutics ($3.7B against $43.6M).

Xilio Therapeutics grew revenue faster over the last twelve months (327% versus 121% for Tango Therapeutics).

Xilio Therapeutics keeps more of each dollar of sales as profit, with a net margin of −34.1% compared with −230% at Tango Therapeutics.

Xilio Therapeutics scores higher on the StockData Score (11 against 10 for Tango Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricTNGXXLO
Size and price
Market cap$3.7B$43.6M
Share price$22.11$7.54
Change, 1 year171%−23.8%
Change, 5 years114%−97.3%
Beta (5Y)1.670.03
Employees13776
StockData Score
Total score1011 (better)
Valuation score03 (better)
Growth score2 (better)1
Performance score22
Health score6 (better)5
Dividend score00
Valuation
P/S69.3×0.7× (better)
P/B3.6×0.6× (better)
FCF yield−3.9% (better)−141%
Fair value$9.71$37.97
Margin of safety−128%80.1% (better)
Growth
Revenue growth (TTM)121%327% (better)
Revenue growth, 5Y average52.1%–
Profitability
Operating margin−253%−48.9% (better)
Net margin−230%−34.1% (better)
FCF margin−268%−95.6% (better)
Return on equity−21.3% (better)−55.0%
Financial health
Debt / equity0.000.00
Current ratio50.82 (better)4.25
Altman Z-score45.17 (better)−3.02
Piotroski F-score45 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions127%58.9%
Held by insiders11.7%–
Insider net buying, 12 months−$8.1M$38.3K (better)
Short interest, % of float32.4%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.